Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-1 · 1 trial · 1 indication
A DLT is any of a predefined set of unacceptable adverse events, regardless of cause. DLTs were assessed during the first cycle (4 weeks).
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cisplatin | DRUG | Cisplatin 60 mg/m2 on day 1 of each 28 day cycle |
| S-1 | DRUG | S-1 80 mg/m2 on days 1-21 of each 28 day cycle |
| Sunitinib | DRUG | Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of gastric cancer * Chemonaive patients * Adequate organ function Exclusion Criteria: * Patients who meet the contra-indications of S-1 and Cisplatin. * Prior chemotherapy failure patients
S-1 is an investigational small molecule being studied for the treatment of stomach neoplasms, which are tumors of the stomach. It is in Phase 1 clinical development for this oncology indication.
S-1 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
S-1 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of stomach neoplasms.
S-1 has been studied in a completed Phase 1 clinical trial with the identifier NCT00553696. This trial, titled "Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer," enrolled 27 participants in Japan and was an uncontrolled, non-randomized study.
S-1 is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in the available information, so its precise mechanism of action is not detailed here.